Masonic cancer center, university of minnesota to present data in poster presentation human data readout for phase 1 study to evaluate hcw9218 in solid tumors at sitc 38th annual meeting

Miramar, fla., nov. 01, 2023 (globe newswire) -- hcw biologics inc. (the “company” or “hcw biologics”) (nasdaq: hcwb), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, will have a human data readout at the 38th annual meeting of the society for immunotherapy of cancer (“sitc”) from an ongoing phase 1 clinical trial to evaluate hcw9218 in patients with chemo-refractory/chemo-resistant solid tumors, conducted by the masonic cancer center, university of minnesota.
HCWB Ratings Summary
HCWB Quant Ranking